[{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","upfrontCash":"$750.0 million","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MorphoSys","amount2":2,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"","sponsorNew":"MorphoSys \/ Incyte","highestDevelopmentStatusID":"9","companyTruncated":"MorphoSys \/ Incyte"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Large molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"CD38","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Xencor","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"MorphoSys \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ MorphoSys"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ I-Mab","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys \/ I-Mab"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ MorphoSys","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys \/ MorphoSys"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Xencor","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Lenalidomide","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Xencor","highestDevelopmentStatusID":"1","companyTruncated":"MorphoSys \/ Xencor"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"MorphoSys \/ MorphoSys","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ MorphoSys"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Constellation Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"$1,700.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Pelabresib","moa":"BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":1.7,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ MorphoSys","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ MorphoSys"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MorphoSys \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ MorphoSys"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MorphoSys \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ MorphoSys"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","upfrontCash":"$1,425.0 million","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved","graph3":"MorphoSys","amount2":2.0299999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":2.0299999999999998,"dosageForm":"","sponsorNew":"MorphoSys \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ Royalty Pharma"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Lenalidomide","moa":"CD47","graph1":"Oncology","graph2":"Preclinical","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"MorphoSys \/ Pfizer"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"CD38","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ I-Mab","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ I-Mab"},{"orgOrder":0,"company":"MorphoSys","sponsor":"InnoCare Pharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MorphoSys \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ MorphoSys"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Otilimab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tulmimetostat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Neurology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MorphoSys \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Roche"},{"orgOrder":0,"company":"MorphoSys","sponsor":"HIBio","pharmaFlowCategory":"D","upfrontCash":"$15.0 million","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Large molecule","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Felzartamab","moa":"CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"MorphoSys","amount2":1.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.02,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ HIBio","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ HIBio"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tulmimetostat","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"$2,897.9 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":2.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.8999999999999999,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Tafasitamab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys \/ Incyte Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pelabresib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Novartis Pharmaceuticals Corporation"}]
Find Clinical Drug Pipeline Developments & Deals by MorphoSys
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
